| |
Total (n = 346)
|
DOAC (n = 74)
|
Vitamin K antagonist (n = 272)
|
p
|
|---|
|
Anticoagulation indication
|
|
Not specified
|
27
|
(7.8)
|
10
|
(13.5)
|
17
|
(6.2)
| |
|
Atrial fibrillation
|
223
|
(64.5)
|
48
|
(64.9)
|
175
|
(64.3)
| |
|
Thromboembolic event
|
74
|
(21.4)
|
13
|
(17.6)
|
61
|
(22.4)
| |
|
Mechanical heart-valve
|
17
|
(4.9)
|
1
|
(1.4)
|
16
|
(5.9)
| |
|
Coagulopathy
|
5
|
(1.4)
|
2
|
(2.7)
|
3
|
(1.1)
|
0.090
|
|
Additional platelet aggregation inhibitor therapy
|
|
None
|
285
|
(82.4)
|
62
|
(83.8)
|
223
|
(82.0)
| |
|
Acetylsalicylic acid
|
44
|
(12.7)
|
9
|
(12.2)
|
35
|
(12.9)
| |
|
Clopidogrel
|
13
|
(3.8)
|
1
|
(1.4)
|
12
|
(4.4)
| |
|
Acetylsalicylic acid + Clopidogrel
|
4
|
(1.2)
|
2
|
(2.7)
|
2
|
(0.7)
|
0.328
|
|
Additional heparin
|
7
|
(2.0)
|
1
|
(1.4)
|
6
|
(2.2)
|
0.643
|
- Abbreviation: DOAC direct oral anticoagulants
